We are live on
!
Find out more
DY
Dowling & Yahnke Portfolio holdings
AUM
$2.15B
Turnover
6.98%
1-Year Est. Return
10.82%
This Fund
S&P 500
This Quarter
Est. Return
-11.83%
1 Year Est. Return
-10.82%
3 Year Est. Return
+34.82%
5 Year Est. Return
+71.23%
10 Year Est. Return
–
AUM
$2.13B
AUM Growth
-$175M
(-7.6%)
Cap. Flow
+$135M
Cap. Flow
% of AUM
6.37%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
393
New
18
Increased
166
Reduced
132
Closed
19
Avg Time Held
5.3
years
Top 10 Avg Time Held
2.5
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dimensional US Marketwide Value ETF
DFUV
|
+$34.5M |
| 2 |
Vanguard Total Bond Market
BND
|
+$24.6M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$19.6M |
| 4 |
Vanguard FTSE All-World ex-US ETF
VEU
|
+$18.6M |
| 5 |
JPMorgan Ultra-Short Municipal Income ETF
JMST
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$44.4M |
| 2 |
Vanguard Emerging Markets Government Bond ETF
VWOB
|
+$5.22M |
| 3 |
Vanguard Morningstar Small-Cap Growth ETF
VBK
|
+$5.21M |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$1.26M |
| 5 |
Reliance Steel & Aluminium
RS
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 48.96% |
| 2 | Technology | 11.56% |
| 3 | Healthcare | 9.67% |
| 4 | Financials | 6.9% |
| 5 | Consumer Staples | 6.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
351
iShares S&P Mid-Cap 400 Growth ETF
IJK
$10.4B
| $209K | 0.01% |
3,276
| – | – |
2017 Q1
21 quarters
|
|
352
iShares US Medical Devices ETF
IHI
$3.74B
| $207K | 0.01% |
4,098
-24
| -0.6% | -$1.31K |
2021 Q3
3 quarters
|
|
353
Altria Group
MO
$125B
| $206K | 0.01% |
4,921
+56
| +1% | +$2.9K |
2013 Q2
36 quarters
|
|
354
Ulta Beauty
ULTA
$25.6B
| $206K | 0.01% |
+534
| New | +$212K |
2022 Q2
0 quarters
|
|
355
Fastenal
FAST
$58.1B
| $203K | 0.01% |
8,132
+150
| +2% | +$4.04K |
2020 Q4
6 quarters
|
|
356
Kinder Morgan
KMI
$75B
| $198K | 0.01% |
11,821
-616
| -5% | -$11.5K |
2017 Q4
18 quarters
|
|
357
Guggenheim Strategic Opportunities Fund
GOF
$1.9B
| $167K | 0.01% |
10,365
+300
| +3% | +$5.31K |
2022 Q1
1 quarter
|
|
358
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $167K | 0.01% |
7,523
| – | – |
2019 Q3
11 quarters
|
|
|
RNAM
359
DELISTED
Avidity Biosciences
RNAM
| $164K | 0.01% |
11,281
| – | – |
2021 Q1
5 quarters
|
|
360
iShares US Oil Equipment & Services ETF
IEZ
$340M
| $160K | 0.01% |
10,000
| – | – |
2020 Q4
6 quarters
|
|
361
SelectQuote
SLQT
$59M
| $136K | 0.01% |
55,000
-25,000
| -31% | -$64.1K |
2022 Q1
1 quarter
|
|
362
Viatris
VTRS
$21.2B
| $135K | 0.01% |
12,888
-891
| -6% | -$9.77K |
2020 Q4
6 quarters
|
|
363
DELISTED
Chimerix, Inc.
CMRX
| $133K | 0.01% |
64,055
+10,000
| +18% | +$32.1K |
2019 Q3
11 quarters
|
|
364
Grifois
GRFS
$5.25B
| $130K | 0.01% |
10,955
| – | – |
2013 Q2
36 quarters
|
|
365
Gossamer Bio
GOSS
$52.9M
| $126K | 0.01% |
189
| – | – |
2022 Q1
1 quarter
|
|
|
SNCE
366
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $125K | 0.01% |
+3,113
| New | +$227K |
2022 Q2
0 quarters
|
|
|
TCON
367
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $95K | ﹤0.01% |
2,373
| – | – |
2020 Q1
9 quarters
|
|
368
SiriusXM
SIRI
$9.15B
| $63K | ﹤0.01% |
1,030
| – | – |
2021 Q3
3 quarters
|
|
369
Geron
GERN
$765M
| $61K | ﹤0.01% |
39,047
| – | – |
2020 Q4
6 quarters
|
|
370
Lineage Cell Therapeutics
LCTX
$249M
| $51K | ﹤0.01% |
+32,263
| New | +$42.5K |
2022 Q2
0 quarters
|
|
371
Strata Critical Medical Inc
SRTA
$405M
| $45K | ﹤0.01% |
10,000
| – | – |
2021 Q2
4 quarters
|
|
|
VJET
372
Flyte Aviation, Inc.
VJET
$1.83M
| $21K | ﹤0.01% |
1
| – | – |
2021 Q1
5 quarters
|
|
373
Fortress Biotech
FBIO
$63M
| $17K | ﹤0.01% |
1,333
| – | – |
2019 Q1
13 quarters
|
|
|
STAB
374
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
| $8K | ﹤0.01% |
28,875
| – | – |
2021 Q3
3 quarters
|
|
375
Avantis Emerging Markets Equity ETF
AVEM
$27B
| – | – |
-3,472
| Closed | -$206K | – |
|
Similar funds
AC
APA
IC
SCA
ACM
W
Dowling & Yahnke's Q2 2022 Portfolio in Review
As of Q2 2022, Dowling & Yahnke held 393 positions worth $2.13B, down 7.6% from $2.3B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Dowling & Yahnke deployed $135M of net new capital in Q2 2022, opening 18 new positions and adding to 166 existing holdings. Its largest new stake was Dimensional US Marketwide Value ETF: 1,035,379 shares worth $32.7M.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 45% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vanguard Tax-Exempt Bond Index Fund, an estimated $44.4M trimmed.
- Dowling & Yahnke's largest Q2 2022 buy was Dimensional US Marketwide Value ETF: 1,035,379 shares worth $32.7M.
- Dowling & Yahnke added most to Vanguard Total Bond Market in Q2 2022, an estimated $24.6M increase.
- Dowling & Yahnke's biggest Q2 2022 reduction was Vanguard Tax-Exempt Bond Index Fund, cutting an estimated $44.4M.
- Dowling & Yahnke fully exited Vanguard Russell 2000 ETF in Q2 2022, selling an estimated $696K.
- Dowling & Yahnke's ten largest holdings make up 29% of its $2.13B portfolio in Q2 2022.
- Dowling & Yahnke opened 18 new positions and closed 19 in Q2 2022.
- Dowling & Yahnke's portfolio value fell 7.6% quarter-over-quarter to $2.13B.
Based on Dowling & Yahnke's 13F filing for Q2 2022, filed 10 Aug 2022.